Overview

RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS

Status:
Active, not recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
A randomized trial of long-term dosage of rituximab in multiple sclerosis
Phase:
Phase 3
Details
Lead Sponsor:
Karolinska Institutet
Treatments:
Rituximab